Next Generation Research Grant in ALS and Related Disorder

Next Generation Research Grant in ALS and Related Disorder is sponsored by American Brain Foundation / CReATe Consortium. This award supports early career researchers engaged in clinical or preclinical research on ALS, PMA, PLS, FTD, HSP, and MSP.

## 2027 Next Generation Research Grants ###### Launching Research Careers The American Brain Foundation’s Next Generation Research Grants fund and support innovative investigations by the best and brightest early-career researchers.

These grants are typically limited to investigators who are interested in an academic career in neurological research and have completed residency or a PhD no more than 5 years prior to the beginning of the award (7 years for the Richard Olney ALS grant). Applications for 2027 grants will close October 8, 2026, except where noted. Funding will begin July 1, 2027.

See an overview of 2027 grants availableor check out the FAQ. * ALS (2-year), funded by The ALS Association and the American Brain Foundation. * ALS and Related Disorders (2-year), funded by CReATe Consortium and the American Brain Foundation.

* Richard Olney Clinician Scientist Grant (3-year), funded by The ALS Association and the American Brain Foundation. #### ASXL-Related Neurodevelopmental Diseases Funded by the ASXL Rare Research Endowment and American Brain Foundation. **_Applications have closed.

_** Funded by the McKnight Brain Research Foundation through the American Brain Foundation. Awarded in collaboration with the American Academy of Neurology. _Applications open until September 10, 2026.

_ Funded by the American Epilepsy Society, Epilepsy Foundation, and the American Brain Foundation. Funded by the American Brain Foundation. For research with potential relevance for more than one condition.

Priority areas include: mental health and neuropsychiatry; women’s health; prevention and resilience; and Alzheimer’s and dementia. #### Mal de Débarquement Syndrome and Central Vestibular Disorders Funded by the MdDS Balance Disorder Foundation through the American Brain Foundation. #### Neuromuscular Disease Funded by the Neuromuscular Study Group and the American Brain Foundation.

Funded by the Parkinson’s Foundation and the American Brain Foundation. Awarded in collaboration with the American Academy of Neurology. _Applications open until September 10, 2026.

_ #### Peripheral Neuropathy Funded by The Foundation for Peripheral Neuropathy through the American Brain Foundation. Funded by the American Heart Association and the American Brain Foundation. Awarded in collaboration with the American Academy of Neurology.

_Applications open until September 10, 2026. _ Check out current recipients and their projects here. For more information or questions about the Next Generation Research Grants program, please contact grants@americanbrainfoundation.

org. ## Cure One, Cure Many Awards There will not be a Cure One, Cure Many Award RFP in 2026. **The 2025 Cure One, Cure Many Award in Neuroinflammation** is a groundbreaking, multimillion-dollar research initiative focused on better understanding neuroinflammation’s role in brain disease, and promises to transform the future of brain health.

It will be carried out through two types of grants s upporting high-risk, high-reward translational research with a focus on clinical impact.

* Two Breakthrough Grants of up to US $2 million each (up to $1 million per year for two years) * At least two Catalyst Grants of up to US $500,000 (up to $250,000 per year for two years) Insights into neuroinflammation’s role in brain health will allow us to more precisely target diseases as different as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, ALS, stroke, brain tumor, epilepsy, migraine, encephalitis, chronic pain, myopathy and neuropathy, traumatic brain injury, schizophrenia, autism and COVID-19-associated brain disease.

Together, these diseases affect 60% of the U.S. population and at least 3 billion people worldwide. They attack the essence of what makes us human: thought, speech, emotion, and movement. Recipients have been selected.

Learn about their projects here. **The 2025 Cure One, Cure Many Award in Lewy Body Dementia**seeks applications aimed for discovery, validation, and acceleration of Lewy body dementia (LBD)-related biomarkers. The ABF intends to award a single grant of up to US $2 million for a budget period of up to 3 years.

LBD is the second most common progressive dementia after Alzheimer’s disease and affects millions of individuals worldwide. When an individual presents with cognitive impairment, however, there virtually no tools available to enable a clinician to make an accurate diagnosis of LBD.

The lack of validated biomarkers for LBD contributes to delayed diagnosis and misdiagnosis, and thus potentially exposes individuals affected by LBD to inappropriate medication use and results in the failure to treat LBD-specific manifestations. The absence of biomarkers also impedes pertinent clinical and translational research, including drug and biomarker discovery efforts. Recipients have been selected.

Learn about their projects here. The American Brain Foundation supports world-class research on cutting edge projects. Funding research across a broad spectrum of the brain and nervous system is the best hope for curing brain disease as a whole.